Pharmacokinetic and Mass Spectrometry Core

maintains mass spectrometry instruments and the technical expertise to design quantitative assays for drug-like compounds.

Contacts

Bo Wen, PhD
734-615-3470
wenb@med.umich.edu

Location

NCRC Building 520 (Rm 3400)
1600 Huron Parkway, Ann Arbor, MI

Affiliations
Pharmacy

Who We Serve

University of Michigan Researchers and External Researchers

Core Summary

We help researchers make informed decisions about the discovery, development, and refinement of therapeutics. Our facility maintains state-of-the-art mass spectrometry instruments and the technical expertise to design quantitative assays for drug-like compounds to aid lead optimization. We perform pre-clinical studies for investigators to answer key questions such as oral bioavailability, plasma protein binding, tissue biodistribution, and metabolite identification by doing quantitative LC-MS analysis of molecules and mass spectrometry imaging of spatial localization biomarkers in tissue section. We also support translation of exposure-response relationships in preclinical disease models to aid dose justification and drug repurposing considerations.  Clinical pharmacokinetic (PK) studies that require bioanalysis, optimal sampling time determination, sample handling and storage, and data analysis (non-compartmental, compartmental, population-PK) are also supported.

Service Categories: Animal Research; Chemical, Material and Protein Characterization ; Human Research ; Molecular Biology

Services

  • Advanced mass spectrometry application
    Biomarker identification and characterization, Mass spectrometry imaging on tissue samples, Targeted lipidomics, Targeted metabolomics,

  • Clinical Pharmacokinetic studies
    Clinical study development, Data analysis with non-compartment model, Modeling with Population-PK analysis, Precision medicine,

  • In vitro and In vivo ADME
    Customer designed animal PK study, Cytochrome P450 inhibition, induction, In vivo complete PK study, In vivo PK screening study, Max tolerated dose, Metabolite identification, Microsomal, Plasma, S9, Hepatocyte stability, Oral bioavailability of drugs, Plasma protein binding, Tissue bioanalysis,

  • LCMS bioanalysis
    Bioanalysis for clinical study, Bioanalysis method development, Chemical compound identification, Drug and metabolite analysis, Method transfer and method qualification, Quantitative analysis,


Equipment

  • 3200 Qtrap Mass spec with HPLC 3200
    Sciex, Equipment Available For Use
  • 4000 Mass spec with HPLC 4000
    Sciex, Equipment Available For Use
  • 4500 Qtrap Mass spec with HPLC 4500
    Sciex, Core Use Only
  • 5500 Qtrap Mass spec with HPLC 5500
    Sciex, Core Use Only
  • 6600+ TripleTof Mass spec with UPLC 6600
    Sciex, Equipment Available For Use
  • AP-MALDI
    MassTech, Equipment Available For Use
  • Cryostat cm1950
    Leica, Equipment Available For Use
  • Homogenizer Evolution
    Precellys, Equipment Available For Use
  • HPLC-UV
    Shimadzu, Equipment Available For Use
  • HPLC-UV 1200
    Agilent, Equipment Available For Use
  • Orbitrap ID-X Tribrid MS with UPLC ID-X
    Thermo, Core Use Only
  • Prep-HPLC-UV
    Shimadzu, Equipment Available For Use
  • TM-Sprayer
    HTX, Equipment Available For Use
  • X500R QTof Mass spec with HPLC X500R
    Sciex, Equipment Available For Use
  • XEVO TQD Mass spec with UPLC TQD
    Waters, Core Use Only